nach oben

Arthritis Research & Therapy

Erschienen in:

01.08.2004 | Review

Role of RUNX in autoimmune diseases linking rheumatoid arthritis, psoriasis and lupus

verfasst von: Marta E Alarcón-Riquelme

Erschienen in: Arthritis Research & Therapy | Ausgabe 4/2004

Einloggen, um Zugang zu erhalten

Abstract

Recent studies investigating the genetic susceptibility of systemic lupus erythematosus, rheumatoid arthritis and psoriasis have revealed a potential role for the RUNX proteins in the development of autoimmune disease. A new pathway of disease pathogenesis opens new avenues of research with thousands of questions that remain to be answered. In this review I attempt to propose how the RUNX proteins might be involved in these diseases and review current knowledge on this very interesting trio of transcription factors that was previously only suspected to be involved in cancer.

Prokunina L, Castillejo-Lopez C, Oberg F, Gunnarsson I, Berg L, Magnusson V, Brookes AJ, Tentler D, Kristjansdottir H, Grondal G, et al: A regulatory polymorphism in PDCD1 is associated with susceptibility to systemic lupus erythematosus in humans. Nat Genet. 2002, 32: 666-669. 10.1038/ng1020.CrossRefPubMed

Nielsen C, Hansen D, Husby S, Jacobsen BB, Lillevang ST: Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens. 2003, 62: 492-497. 10.1046/j.1399-0039.2003.00136.x.CrossRefPubMed

Prokunina L, Padyukov L, Bennet A, De Faire U, Wiman B, Prince J, Alfredsson L, Klareskog L, Alarcón-Riquelme ME: Association of the PD1.3 A allelle of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum. 2004, 50: 1770-1773. 10.1002/art.20280.CrossRefPubMed

Helms C, Cao L, Krueger JG, Wijsman EM, Chamian F, Gordon D, Heffernan M, Daw JA, Robarge J, Ott J, et al: A putative RUNX1 binding site variant between SLC9A3R1 and NAT9 is associated with susceptibility to psoriasis. Nat Genet. 2003, 35: 349-56. 10.1038/ng1268.CrossRefPubMed

Tokuhiro S, Yamada R, Chang X, Suzuki A, Kochi Y, Sawada T, Suzuki M, Nagasaki M, Ohtsuki M, Ono M, et al: An intronic SNP in a RUNX1 binding site of SLC22A4, encoding an organic cation transporter, is associated with rheumatoid arthritis. Nat Genet. 2003, 35: 341-348. 10.1038/ng1267.CrossRefPubMed

John S, Eyre S, Myerscough A, Barrett J, Silman A, Ollier W, Worthington J: Linkage and association analysis of candidate genes in rheumatoid arthritis. J Rheumatol. 2001, 28: 1752-1755.PubMed

Rioux JD, Daly MJ, Silverberg MS, Lindblad K, Steinhart H, Cohen Z, Delmonte T, Kocher K, Miller K, Guschwan S, et al: Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet. 2001, 29: 223-228. 10.1038/ng1001-223.CrossRefPubMed

Otto F, Lubbert M, Stock M: Upstream and downstream targets of RUNX proteins. J Cell Biochem. 2003, 89: 9-18. 10.1002/jcb.10491.CrossRefPubMed

Tahirov TH, Inoue-Bungo T, Morii H, Fujikawa A, Sasaki M, Kimura K, Shiina M, Sato K, Kumasaka T, Yamamoto M, et al: Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta. Cell. 2001, 104: 755-767.CrossRefPubMed

10.

Backstrom S, Huang SH, Wolf-Watz M, Xie XQ, Hard T, Grundstrom T, Sauer UH: Crystallization and preliminary studies of the DNA-binding runt domain of AML1. Acta Crystallogr D Biol Crystallogr. 2001, 57: 269-271. 10.1107/S0907444900015791.CrossRefPubMed

11.

Rennert J, Coffman JA, Mushegian AR, Robertson AJ: The evolution of Runx genes I. A comparative study of sequences from phylogenetically diverse model organisms. BMC Evol Biol. 2003, 3: 4-10.1186/1471-2148-3-4.PubMedCentralCrossRefPubMed

12.

Coffman JA: Runx transcription factors and the developmental balance between cell proliferation and differentiation. Cell Biol Int. 2003, 27: 315-324. 10.1016/S1065-6995(03)00018-0.CrossRefPubMed

13.

Barton K, Nucifora G: AML1 haploinsufficiency, gene dosage, and the predisposition to acute leukemia. BioEssays. 2000, 22: 214-218. 10.1002/(SICI)1521-1878(200003)22:3<214::AID-BIES2>3.3.CO;2-9.CrossRefPubMed

14.

Erickson P, Gao J, Chang KS, Look T, Whisenant E, Raimondi S, Lasher R, Trujillo J, Rowley J, Drabkin H: Identification of breakpoints in t(8;21) acute myelogenous leukemia and isolation of a fusion transcript, AML1/ETO, with similarity to Drosophila segmentation gene, runt. Blood. 1992, 80: 1825-1831.PubMed

15.

Guerrasio A, Rosso C, Martinelli G, Lo Coco F, Pampinella M, Santoro A, Lanza C, Allione B, Resegotti L, Saglio G: Polyclonal haemopoieses associated with long-term persistence of the AML1-ETO transcript in patients with FAB M2 acute myeloid leukaemia in continous clinical remission. Br J Haematol. 1995, 90: 364-368.CrossRefPubMed

16.

Kozu T, Miyoshi H, Shimizu K, Maseki N, Kaneko Y, Asou H, Kamada N, Ohki M: Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction. Blood. 1993, 82: 1270-1276.PubMed

17.

Uchida H, Downing JR, Miyazaki Y, Frank R, Zhang J, Nimer SD: Three distinct domains in TEL-AML1 are required for transcriptional repression of the IL-3 promoter. Oncogene. 1999, 18: 1015-1022. 10.1038/sj.onc.1202383.CrossRefPubMed

18.

Song H, Kim JH, Rho JK, Park SY, Kim CG, Choe SY: Functional characterization of TEL/AML1 fusion protein in the regulation of human CR1 gene promoter. Mol Cells. 1999, 9: 560-563.PubMed

19.

Romana SP, Mauchauffe M, Le Coniat M, Chumakov I, Le Paslier D, Berger R, Bernard OA: The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood. 1995, 85: 3662-3670.PubMed

20.

Kurokawa M, Ogawa S, Tanaka T, Mitani K, Yazaki Y, Witte ON, Hirai H: The AML1/Evi-1 fusion protein in the t(3;21) translocation exhibits transforming activity on Rat1 fibroblasts with dependence on the Evi-1 sequence. Oncogene. 1995, 11: 833-840.PubMed

21.

Lutterbach B, Hou Y, Durst KL, Hiebert SW: The inv(16) encodes an acute myeloid leukemia 1 transcriptional corepressor. Proc Natl Acad Sci USA. 1999, 96: 12822-12827. 10.1073/pnas.96.22.12822.PubMedCentralCrossRefPubMed

22.

Okuda T, Nishimura M, Nakao M, Fujita Y: RUNX1/AML1: a central player in hematopoiesis. Int J Hematol. 2001, 74: 252-257.CrossRefPubMed

23.

Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, Ratajczak J, Resende IC, Haworth C, Hock R, et al: Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999, 23: 166-175. 10.1038/13793.CrossRefPubMed

24.

Michaud J, Wu F, Osato M, Cottles GM, Yanagida M, Asou N, Shigesada K, Ito Y, Benson KF, Raskind WH, et al: In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis. Blood. 2002, 99: 1364-1372. 10.1182/blood.V99.4.1364.CrossRefPubMed

25.

Komori T: Requisite roles of Runx2 and Cbfb in skeletal development. J Bone Miner Metab. 2003, 21: 193-197.PubMed

26.

Kundu M, Javed A, Jeon JP, Horner A, Shum L, Eckhaus M, Muenke M, Lian JB, Yang Y, Nuckolls GH, et al: Cbfβ interacts with Runx2 and has a critical role in bone development. Nat Genet. 2002, 32: 639-644. 10.1038/ng1050.CrossRefPubMed

27.

Lian JB, Balint E, Javed A, Drissi H, Vitti R, Quinlan EJ, Zhang L, Van Wijnen AJ, Stein JL, Speck N, et al: Runx1/AML1 hematopoietic transcription factor contributes to skeletal development in vivo. J Cell Physiol. 2003, 196: 301-311. 10.1002/jcp.10316.CrossRefPubMed

28.

Inoue K, Ozaki S, Ito K, Iseda T, Kawaguchi S, Ogawa M, Bae SC, Yamashita N, Itohara S, Kudo N, et al: Runx3 is essential for the target-specific axon pathfinding of trkc-expressing dorsal root ganglion neurons. Blood Cells Mol Dis. 2003, 30: 157-160. 10.1016/S1079-9796(03)00032-9.CrossRefPubMed

29.

Moss SF: RUNX 3, apoptosis 0: a new gastric tumour suppressor. Gut. 2003, 52: 12-13. 10.1136/gut.52.1.12.PubMedCentralCrossRefPubMed

30.

Woolf E, Xiao C, Fainaru O, Lotem J, Rosen D, Negreanu V, Bernstein Y, Goldenberg D, Brenner O, Berke G, et al: Runx3 and Runx1 are required for CD8 T cell development during thymopoiesis. Proc Natl Acad Sci USA. 2003, 100: 7731-7736. 10.1073/pnas.1232420100.PubMedCentralCrossRefPubMed

31.

Taniuchi I, Osato M, Egawa T, Sunshine MJ, Bae SC, Komori T, Ito Y, Littman DR: Differential requirements for Runx proteins in CD4 repression and epigenetic silencing during T lymphocyte development. Cell. 2002, 111: 621-633. 10.1016/S0092-8674(02)01111-X.CrossRefPubMed

32.

Komine O, Hayashi K, Natsume W, Watanabe T, Seki Y, Seki N, Yagi R, Sukzuki W, Tamauchi H, Hozumi K, et al: The Runx1 transcription factor inhibits the differentiation of naive CD4+ T cells into the Th2 lineage by repressing GATA3 expression. J Exp Med. 2003, 198: 51-61. 10.1084/jem.20021200.PubMedCentralCrossRefPubMed

33.

Fainaru O, Woolf E, Lotem J, Yarmus M, Brenner O, Goldenberg D, Negreanu V, Bernstein Y, Levanon D, Jung S, et al: Runx3 regulates mouse TGF. EMBO J. 2004, 23: 969-979. 10.1038/sj.emboj.7600085.PubMedCentralCrossRefPubMed

34.

Petrow PK, Hummel KM, Schedel J, Franz JK, Klein CL, Muller-Ladner U, Kriegsmann J, Chang PL, Prince CW, Gay RE, et al: Expression of osteopontin messenger RNA and protein in rheumatoid arthritis: effects of osteopontin on the release of collagenase 1 from articular chondrocytes and synovial fibroblasts. Arthritis Rheum. 2000, 43: 1597-1605. 10.1002/1529-0131(200007)43:7<1597::AID-ANR25>3.3.CO;2-S.CrossRefPubMed

35.

Ohshima S, Yamaguchi N, Nishioka K, Mima T, Ishii T, Umeshita-Sasai M, Kobayashi H, Shimizu M, Katada Y, Wakitani S, et al: Enhanced local production of osteopontin in rheumatoid joints. J Rheumatol. 2002, 29: 2061-2067.PubMed

36.

Stricker S, Fundele R, Vortkamp A, Mundlos S: Role of Runx genes in chondrocyte differentiation. Dev Biol. 2002, 245: 95-108. 10.1006/dbio.2002.0640.CrossRefPubMed

37.

Ballara S, Taylor PC, Reusch P, Marme D, Feldmann M, Maini RN, Paleolog EM: Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum. 2001, 44: 2055-2064. 10.1002/1529-0131(200109)44:9<2055::AID-ART355>3.0.CO;2-2.CrossRefPubMed

38.

Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN: Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. Arthritis Rheum. 1998, 41: 1258-1265. 10.1002/1529-0131(199807)41:7<1258::AID-ART17>3.0.CO;2-1.CrossRefPubMed

39.

Lindy O, Konttinen YT, Sorsa T, Ding Y, Santavirta S, Ceponis A, Lopez-Otin C: Matrix metalloproteinase 13 (collagenase 3) in human rheumatoid synovium. Arthritis Rheum. 1997, 40: 1391-1399.CrossRefPubMed

40.

Detmar M: Evidence for vascular endothelial growth factor (VEGF) as a modifier gene in psoriasis. J Invest Dermatol. 2004, 122: xiv-xv. 10.1046/j.0022-202X.2003.22140.x.CrossRefPubMed

41.

Balomenos D, Martin-Caballero J, Garcia MI, Prieto I, Flores JM, Serrano M, Martinez AC: The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat Med. 2000, 6: 171-176. 10.1038/72272.CrossRefPubMed

42.

Iida K, Mornaghi R, Nussenzweig V: Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med. 1982, 155: 1427-1438. 10.1084/jem.155.5.1427.CrossRefPubMed

43.

Moulds JM, Reveille JD, Arnett FC: Structural polymorphisms of complement receptor 1 (CR1) in systemic lupus erythematosus (SLE) patients and normal controls of three ethnic groups. Clin Exp Immunol. 1996, 105: 302-305. 10.1046/j.1365-2249.1996.d01-748.x.PubMedCentralCrossRefPubMed

44.

Banerjee C, Hiebert SW, Stein JL, Lian JB, Stein GS: An AML-1 consensus sequence binds an osteoblast-specific complex and transcriptionally activates the osteocalcin gene. Proc Natl Acad Sci USA. 1996, 93: 4968-4973. 10.1073/pnas.93.10.4968.PubMedCentralCrossRefPubMed

45.

Hoffmann HM, Beumer TL, Rahman S, McCabe LR, Banerjee C, Aslam F, Tiro JA, van Wijnen AJ, Stein JL, Stein GS, et al: Bone tissue-specific transcription of the osteocalcin gene: role of an activator osteoblast-specific complex and suppressor hox proteins that bind the OC box. J Cell Biochem. 1996, 61: 310-324. 10.1002/(SICI)1097-4644(19960501)61:2<310::AID-JCB14>3.0.CO;2-P.CrossRefPubMed

46.

Prince M, Banerjee C, Javed A, Green J, Lian JB, Stein GS, Bodine PV, Komm BS: Expression and regulation of Runx2/Cbfa1 and osteoblast phenotypic markers during the growth and differentiation of human osteoblasts. J Cell Biochem. 2001, 80: 424-440. 10.1002/1097-4644(20010301)80:3<424::AID-JCB160>3.0.CO;2-6.CrossRefPubMed

47.

Bae SC, Lee KS, Zhang YW, Ito Y: Intimate relationship between TGF-beta/BMP signaling and runt domain transcription factor, PEBP2/CBF. J Bone Joint Surg Am. 2001, 83-A (Suppl 1): S48-S55.PubMed

48.

Leboy P, Grasso-Knight G, D'Angelo M, Volk SW, Lian JV, Drissi H, Stein GS, Adams SL: Smad-Runx interactions during chondrocyte maturation. J Bone Joint Surg Am. 2001, 83-A (Suppl 1): S15-S22.PubMed

49.

Ito Y, Miyazono K: RUNX transcription factors as key targets of TGF-beta superfamily signaling. Curr Opin Genet Dev. 2003, 13: 43-47. 10.1016/S0959-437X(03)00007-8.CrossRefPubMed

50.

Alarcon-Riquelme ME: A RUNX trio with a taste for autoimmunity. Nat Genet. 2003, 35: 299-300. 10.1038/ng1203-299.CrossRefPubMed

Titel: Role of RUNX in autoimmune diseases linking rheumatoid arthritis, psoriasis and lupus
verfasst von: Marta E Alarcón-Riquelme
Publikationsdatum: 01.08.2004
Verlag: BioMed Central
Erschienen in: Arthritis Research & Therapy / Ausgabe 4/2004
Elektronische ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar1203

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2004

Ageing, autoimmunity and arthritis: Senescence of the B cell compartment – implications for humoral immunity

Measurement of global functional performance in patients with rheumatoid arthritis using rheumatology function tests

What should be the core outcomes in chronic pain clinical trials?

CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease

Targeting the interleukin-15/interleukin-15 receptor system in inflammatory autoimmune diseases